Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
  • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
  • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D237/20—Nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/275—Nitriles; Isonitriles
  • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/64—One oxygen atom attached in position 2 or 6
  • C07D213/643—2-Phenoxypyridines; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/79—Acids; Esters
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D263/36—One oxygen atom
  • C07D263/40—One oxygen atom attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
  • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
  • C07D493/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/07—Optical isomers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
  • C07C2601/14—The ring being saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
  • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
  • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

• Described in this specification are compounds (including salts thereof) that are modulators of RXFP1, uses of such compounds, compositions containing such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.
• Relaxin is a pleiotropic hormone known to mediate systemic haemodynamic and renal adaptive changes during pregnancy. Relaxin has also been shown to have anti-fibrotic properties and to have beneficial effects in heart failure e.g. with acute decompensated heart failure (ADHF). Heart failure is associated with significant morbidity and mortality. It is characterized by complex tissue remodelling involving increased cardiomyocyte death and interstitial fibrosis. Relaxin activates a number of signalling cascades which have been shown to be beneficial in the setting of ischemia-reperfusion and heart failure. These signalling pathways include activation of the phosphoinositide 3 -kinase pathway and activation of the nitric oxide signalling pathway (Bathgate RA et al.
• RXFP1 The cognate receptor for human relaxin is RXFP1 and is a well-validated pharmacologically important GPCR family 1c member whose activation by the hormone relaxin is associated with hemodynamic, anti-fibrotic and anti-inflammatory properties (Halls ML et al., (2015), Pharmacol Rev. 67(2): 389-440).
• Small-molecule modulators of RXFP1 have been sought as relaxin mimetics. For example, Marugan, J. J., et al., WO2013/165606A1; Xiao J et al. (2013) Nat. Commun. 4: 1953; and McBride A et al. (2017) Scientific Reports 7: 10806 discuss small-molecule modulators of RXFP1.
• the compound(s) of the invention may also exhibit improved modulation of RXFP1 in comparison with other known RXFP1 modulators.
• the compound(s) of the invention may also exhibit favourable pharmacokinetic profiles (for example, lower intrinsic clearance) and/or advantageous physical properties (for example, higher aqueous solubility) in comparison with other known RXFP1 modulators. Therefore, such compound(s) may be especially useful in the treatment of disease states in which modulation of RXFP1 is beneficial.
• Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; or a 4- to 10-membered cycloalkenyl;
• R 7 is selected from -H, -F, -CH 3 and -OCH 3 ; each R 8 is independently selected from C 1-4 alkyl substituted with 0-3 -F substituents; C 1 - 4 alkoxy; -OH; -F; and -COO( C 1-4 alkyl);
• p is 0, 1 or 2;
• 5 Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycl
• This specification also describes, in part, a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
• This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy.
• This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or condition selected from the group consisting of heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury.
• This specification also describes, in part, the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury.
• This specification also describes, in part, a method for treating a disease or condition selected from the group consisting of heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
• This specification also describes, in part, an Intermediate compound (as described herein), or a salt thereof. This specification also describes, in part, a process for preparing a compound of Formula
• Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having
• R 7 is selected from -H, -F, -CH 3 and -OCH 3
• each R 8 is independently selected from C 1-4 alkyl substituted with 0-3 -F substituents; C 1 - 4 alkoxy; -OH; -F; and -COO(C 1-4 alkyl);
• p is 0, 1 or 2
• Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen
• each R 9 is independently selected fromC 1-4 alkyl,C 1-4 alkoxy, -
• R 4 is selected from -H, -halo, -CN, C 1-4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1-4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me; or (iii) V and W are each C;
• R 3 and R 4 together with the atoms to which they are attached, form a 5- or 6- membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-3 -Me substituents;
• R 2 is selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me.
• Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; or a 4- to 10-membered cycloalkenyl.
• Ring B is a monocyclic 5- to 7-membered cycloalkyl optionally bridged with C 1.3 alkylene; a monocyclic 5- to 7-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen and optionally bridged with C 1.3 alkylene; a monocyclic 5- to 7-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen and optionally bridged with C 1.3 alkylene; or a monocyclic 5- to 7-membered cycloalkenyl optionally bridged with C 1.3 alkylene.
• Ring B is a 4- to 10-membered cycloalkyl, or a 4- to 10-membered cycloalkenyl.
• Ring B is a 5- to 8-membered cycloalkyl, or a 5- to 8-membered cycloalkenyl.
• Ring B is a monocyclic 5- to 7-membered cycloalkyl optionally bridged with C 1.3 alkylene; or a monocyclic 5- to 7-membered cycloalkenyl optionally bridged with C 1.3 alkylene.
• Ring B is cyclohexyl optionally bridged with C 1.2 alkylene, or cyclohexenyl optionally bridged with C 1.2 alkylene.
• Ring B is cyclohexyl 1,4-bridged with C 1.2 alkylene, or cyclohexenyl 1,4-bridged with C 1-2 alkylene.
• Ring B is bicyclo[2.2.1]heptanyl or bicyclo[2.2.1]hept-2-enyl.
• Ring B is bicyclo[2.2. l]heptanyl.
• R 7 is selected from -H, -F, -CH 3 and -OCH 3 .
• R 7 is selected from -H and -F.
• R 7 is -H.
• each R 8 is independently selected from C 1.4 alkyl substituted with 0-3 -F substituents; C 1 - 4 alkoxy; -OH; -F; and -COO(C 1-4 alkyl).
• each R 8 is independently selected from C 1.2 alkyl substituted with 0-3 -F substituents; C 1 - 2 alkoxy; -OH; and -F.
• each R 8 is independently selected from C 1.2 alkyl substituted with 0-3 -F substituents; and -F.
• each R 8 is independently selected from -Me and -F.
• p is 0, 1 or 2.
• p is 0 or 1.
• p is 0.
• Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen.
• Ring C is phenyl; a monocyclic 5- or 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; a monocyclic 4- to 7-membered cycloalkenyl optionally bridged with C 1.3 alkylene; or a monocyclic 4- to 7-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen and optionally bridged with C 1.3 alkylene.
• Ring C is a monocyclic 5- to 7-membered cycloalkenyl optionally bridged with C 1.2 alkylene; or a monocyclic 5- to 7-membered heterocycloalkenyl having 1 oxygen heteroatom and optionally bridged with C 1.2 alkylene.
• Ring C is a mono- or poly-cyclic 6- to 10-membered aryl.
• Ring C is phenyl
• Ring C is not phenyl.
• each R 9 is independently selected from C 1.4 alkyl, C 1.4 alkoxy, -halo and -OH.
• each R 9 is independently selected from C 1.2 alkyl, C 1.2 alkoxy, -halo and -OH.
• q is 0, 1 or 2.
• q is 0 or 1.
• q is 0.
• R 1 is selected from -COOH, -CONH 2 , -CONHMe, -CONMe 2 , -C(CH 2 OH) 2 NH 2 , -
• R 1 is -COOH or a bioisotere of a carboxylic acid such as tetrazolyl.
• a bioisotere of carboxylic acids will be apparent to a person of skill in the art.
• R 1 is selected from -
• R 1 is -COOH.
• X is selected from a bond, -CH 2 -, -O-, -S-, -CH 2 O- and -OCH 2 -.
• X is selected from a bond, -CH 2 -, -O-, -CH 2 O- and -OCH 2 -.
• X is selected from a bond, -CH 2 -, and -O-.
• X is selected from -CH 2 - and -O-.
• X is -O-.
• Y is selected from C 2-6 alkylene substituted with 0-2 R 14 substituents; C 3-8 cycloalkylene substituted with 0-2 R 14 substituents; C5-8 cycloalkenylene substituted with 0-2 R 14 substituents; 5- to 8-membered heterocycloalkylene having 1-3 heteroatoms independently selected from oxygen and sulfur and substituted with 0-2 R 14 substituents; phenylene substituted with 0-2 R 14 substituents; 5- or 6-membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-2 R 14 substituents; and
• Y is selected from C 2-6 alkylene substituted with 0-1 R 14 substituents; C 3-8 cycloalkylene substituted with 0-1 R 14 substituents; C5-8 cycloalkenylene substituted with 0-1 R 14 substituents; 5- to 8-membered heterocycloalkylene having 1-3 heteroatoms independently selected from oxygen and sulfur and substituted with 0-1 R 14 substituents; phenylene substituted with 0-1 R 14 substituents; 5- or 6-membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-1 R 14 substituents; and
• Y is selected from C 2-4 alkylene substituted with 0-2 R 14 substituents; C 3-8 cycloalkylene substituted with 0-2 R 14 substituents; and 5- to 8-membered heterocycloalkylene having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-2 R 14 substituents.
• Y is selected from C 2-4 alkylene substituted with 0-1 R 14 substituents; C 3-8 cycloalkylene substituted with 0-1 R 14 substituents; and 5- to 8-membered heterocycloalkylene having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-1 R 14 substituents.
• Y is selected from C 4-6 cycloalkylene substituted with 0-1 R 14 substituents; and 5- or 6- membered heterocycloalkylene having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-1 R 14 substituents.
• Y is C 3-8 cycloalkylene substituted with 0-2 R 14 substituents.
• Y is C 4-6 cycloalkylene substituted with 0-2 R 14 substituents.
• Y is C 3-8 cycloalkylene substituted with 0-1 R 14 substituents.
• Y is C 4-6 cycloalkylene substituted with 0-1 R 14 substituents.
• Y is cyclohexylene substituted with 0-2 R 14 substituents.
• Y is cyclohexylene substituted with 0-1 R 14 substituents.
• Y is cyclohexylene substituted with 1 R 14 substituent.
• the X and Z substituents are bonded to Y such that, where there are sufficient ring or chain atoms in Y, the X and Z substituents are not in a geminal or vicinal configuration.
• r is 1, 2 or 3. r is 1 or 2. r is 2.
• R 14 is -H.
• R 14 is not -H.
• R 14 is -Me.
• Z is a bond.
• R 5 is selected from -H, -Me and -F.
• R 5 is -H.
• R 6 is -(CR 10 R 11 ) n R 12 .
• R 6 is -(CR 10 R 11 )R 12 .
• R 6 is -(CH 2 )R 12 .
• R 6 is -R 12 .
• R 6 is selected from R 6 is selected from and .
• R 6 is n is 0, 1 or 2.
• n is 0 or 1.
• n is 0. n is 1.
• R 10 and R 11 are each independently selected from -H, -Me and -F, or R 10 and R 11 together with the carbon to which they are attached form cyclopropyl.
• R 10 and R 11 are each independently selected from -H, -Me and -F.
• R 10 and R 11 are each -H.
• R 12 is selected from C 3-8 alkyl substituted with 0-5 substituents selected from -OH, -F, - CN, and C 1.4 alkoxy; C 3-10 cycloalkyl substituted with 0-4 R 13 substituents; 5- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-4 R 13 substituents; phenyl substituted with 0-3 substituents selected from - halo, C 1.4 alkyl substituted with 0-3 -F substituents, C 3-5 cycloalkyl, -CN, -SF 5 , -OMe, -OCH 2 F, - OCHF 2 , -OCF 3 and -SO 2 CF 3 ; 6-membered heteroaryl having 1-2 nitrogen heteroatoms and substituted with 1-3 substituents selected from -halo, -SF 5 , -CF 3 , -OCF 3 and -SO 2 CF 3 ;
• R 12 is selected from C 3-8 alkyl substituted with 0-3 substituents selected from -OH, -F, - CN, and C 1.4 alkoxy; C 3-10 cycloalkyl substituted with 0-3 R 13 substituents; and 5- to 10- membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-3 R 13 substituents.
• R 12 is selected from C 4-6 alkyl substituted with 0-3 substituents selected from -F, -CN, and C 1-2 alkoxy; C 4-6 cycloalkyl substituted with 0-3 R 13 substituents; and 5- to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-3 R 13 substituents.
• R 12 is selected from C 4-6 alkyl substituted with 0-2 substituents selected from -F, -CN, and C 1-2 alkoxy; C 4-6 cycloalkyl substituted with 0-1 R 13 substituents; and 5- to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-1 R 13 substituents.
• R 12 is selected from C 4-6 alkyl substituted with 0-3 -F substituents; and C 4-6 cycloalkyl substituted with 0-3 substituents selected from -F and -Me.
• R 12 is selected from C 3-6 alkyl substituted with 0-3 -F substituents; and C 3-6 cycloalkyl substituted with 0-3 substituents selected from -F and -Me.
• R 12 is selected from C 3-6 alkyl substituted with 0-3 -F substituents; and C 3-6 cycloalkyl substituted with -F or -Me.
• R 12 is selected from tert-butyl substituted with 0-3 -F substituents; cyclobutyl substituted with 0-2 substituents selected from -F and -Me; and bicyclo[l.l. l]pentanyl substituted with 0-2 substituents selected from -F and -Me.
• R 12 is selected from tert-butyl substituted with 0-3 -F substituents; cyclobutyl substituted with 0-2 substituents selected from -F and -Me; and bicyclo[l.l. l]pentanyl substituted with 0-2 substituents selected from -F and -Me.
• R 12 is selected from tert-butyl substituted with 0-3 -F substituents; cyclobutyl substituted with 0-1 substituents selected from -F and -Me; and bicyclo[l.l. l]pentanyl substituted with 0-2 substituents selected from -F and -Me.
• R 12 is selected from
• R 12 is selected from phenyl substituted with 0-3 substituents selected from -halo, C 1.4 alkyl substituted with 0-3 -F substituents, C 3-5 cycloalkyl, -CN, -SF 5 , -OMe, -OCH 2 F, -OCHF 2 , - OCF 3 and -SO 2 CF 3 ; 6-membered heteroaryl having 1-2 nitrogen heteroatoms and substituted with 1-3 substituents selected from -halo, -SF 5 , -CF 3 , -OCF 3 and -SO 2 CF 3 ;
• R 12 is selected from phenyl substituted with 1-2 substituents selected from -halo, C 1-4 alkyl substituted with 0-3 -F substituents, C 3-5 cycloalkyl, -CN, -SF 5 , -OMe, -OCH 2 F, -OCHF 2 , - OCF 3 and -SO 2 CF 3 .
• R 12 is selected from each R 13 is independently selected from -OH; -F; -CN; C 1.4 alkoxy substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt; and C 1.4 alkyl substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt.
• each R 13 is independently selected from -F; -CN; C 1.2 alkoxy substituted with 0-1 substituents selected from -F, -OMe and -OEt; and C 1.2 alkyl substituted with 0-1 substituents selected from -F, -OMe and -OEt.
• each R 13 is independently selected from -F; -CN; C 1.4 alkoxy; and C 1.4 alkyl. each R 13 is independently selected from -F; C 1.2 alkoxy; and C 1.2 alkyl. each R 13 is independently selected from -F; -OMe; and -Me. each R 13 is -F. each R 13 is -Me.
• U, V and W are each independently selected from C and N; provided that when U is N, R 2 is absent; when V is N, R 3 is absent; and when W is N, R 4 is absent.
• U, V and W are each C.
• R 2 , R 3 and R 4 are each independently selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me.
• R 2 is selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe.
• R 2 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and C 3-4 cycloalkyl substituted with 0-1 substituents selected from -F and -OMe.
• R 2 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and cyclopropyl.
• R 2 is not -H.
• R 2 is -CN or -F.
• R 2 is -CN.
• R 2 is -F.
• R 3 is selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe.
• R 3 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and C 3-4 cycloalkyl substituted with 0-1 substituents selected from -F and -OMe.
• R 3 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and cyclopropyl.
• R 3 is -H.
• R 4 is selected from -H, -F, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me.
• R 4 is selected from -H, -F, and C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe.
• R 4 is selected from -F and C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe.
• R 4 is selected from -F and C 1.3 alkoxy substituted with 0-2 substituents selected from -F and -OMe.
• R 4 is selected from -F and C 1.3 alkoxy substituted with 0-2 substituents selected from -F and -OMe.
• R 4 is C 1.3 alkoxy substituted with 0-2 substituents selected from -F and -OMe.
• R 4 is -OMe or -OEt.
• R 4 is not -H.
• R 4 is selected from -F and -OMe.
• R 4 is -OMe.
• R 2 and R 3 together with the atoms to which they are attached, form a 5- or 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-3 -Me substituents; and U and V are each C.
• R 3 and R 4 together with the atoms to which they are attached, form a 5- or 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-3 -Me substituents; and V and W are each C.
• R 3 and R 4 are selected such that the ring containing R 3 , R 4 , V and W is and wherein said ring is optionally substituted with 0-2 -Me substituents.
• R 3 and R 4 are selected such that the ring containing R 3 , R 4 , V and W is
• R 2 is -CN; R 3 is -H; R 4 is -OMe; and R 5 is -H.
• R 2 is -F; R 3 is -H; R 4 is -OMe; and R 5 is -H.
• Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; or a 4- to 10-membered cycloalkenyl;
• R 7 is selected from -H, -F, -CH 3 and -OCH 3 ; each R 8 is independently selected from C 1.4 alkyl substituted with 0-3 -F substituents; C 1 - 4 alkoxy; -OH; -F; and -COO(C 1-4 alkyl); p is 0, 1 or 2;
• Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; each R 9 is independently selected from C 1.4 alkyl, C 1.4 alkoxy, -halo and -OH; q is 0, 1 or 2;
• R 1 is selected from -COOH, -CONH 2 , -CONHMe, -CONMe 2 , -C(CH 2 OH) 2 NH 2 , -
• X is selected from a bond, -CH 2 -, -O-, -S-, -CH 2 O- and -OCH 2 -;
• Y is selected from C 2 -6 alkylene substituted with 0-2 R 14 substituents; C 3-8 cycloalkylene substituted with 0-2 R 14 substituents; C 5-8 cycloalkenylene substituted with 0-2 R 14 substituents; 5- to 8-membered heterocycloalkylene having 1-3 heteroatoms independently selected from oxygen and sulfur and substituted with 0-2 R 14 substituents; phenylene substituted with 0-2 R 14 substituents; 5- or 6-membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and substituted with 0-2 R 14 substituents; and R 14 is selected from C 1.3 alkyl substituted with 0-3 substituents selected from -OH, -OMe, -F and -CN; C 1.3 alkoxy substituted with 0-3 -F substituents; cyclopropyl substituted with 0-3 substituents selected from -OH, -OMe, -F and -CN; -F;
• R 5 is selected from -H, -Me and -F;
• R 6 is -(CR 10 R u )nR 12 ; n is 0, 1 or 2;
• R 10 and R 11 are each independently selected from -H, -Me and -F, or R 10 and R 11 together with the carbon to which they are attached form cyclopropyl;
• R 12 is selected from C 3-8 alkyl substituted with 0-5 substituents selected from -OH, -F, - CN, and C 1.4 alkoxy; C 3-10 cycloalkyl substituted with 0-4 R 13 substituents; 5- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-4 R 13 substituents; phenyl substituted with 0-3 substituents selected from - halo, C 1.4 alkyl substituted with 0-3 -F substituents, C3-5 cycloalkyl, -CN, -SF 5 , -OMe, -OCH 2 F, - OCHF2, -OCF 3 and -SO 2 CF 3 ; 6-membered heteroaryl having 1-2 nitrogen heteroatoms and substituted with 1-3 substituents selected from -halo, -SF 5 , -CF 3 , -OCF 3 and -SO 2 CF 3 ; each R 13 is
• U, V and W are each independently selected from C and N; provided that when U is N, R 2 is absent; when V is N, R 3 is absent; and when W is N, R 4 is absent;
• R 2 and R 3 are each independently selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me; and R 4 is selected from -F and C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe; optionally R 4 is C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe; optionally R 4 is -OMe.
• Ring B is a 4- to 10-membered cycloalkyl; a 4- to 10-membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; or a 4- to 10-membered cycloalkenyl;
• Ring C is a 6- to 10-membered aryl; a 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 4- to 10-membered cycloalkenyl; or a 4- to 10-membered heterocycloalkenyl having 1-2 heteroatoms independently selected from nitrogen and oxygen; each R 9 is independently selected from C 1-4 alkyl, C 1-4 alkoxy, -halo and -OH; q is 0, 1 or 2, optionally q is 0;
• R 1 is -COOH
• X is selected from a bond, -CH 2 -, -O-, -S-, -CH 2 O- and -OCH 2 -; optionally X is -O-;
• R 5 is selected from -H, -Me and -F, optionally R 5 is -H;
• R 6 is -(CR 10 R u )nR 12 ; n is 0, 1 or 2;
• R 10 and R 11 are each independently selected from -H, -Me and -F, or R 10 and R 11 together with the carbon to which they are attached form cyclopropyl;
• R 12 is selected from C 4-6 alkyl substituted with 0-3 substituents selected from -F, -CN, and C 1-2 alkoxy; C 4-6 cycloalkyl substituted with 0-3 R 13 substituents; and 5- to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from oxygen and sulfur and substituted with 0-3 R 13 substituents; or selected from -halo, -Me, -CF 3 and -CN; each R 13 is independently selected from -OH; -F; -CN; C 1.4 alkoxy substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt; and C 1.4 alkyl substituted with 0-3 substituents selected from -F, -OH, -OMe and -OEt;
• U, V and W are each independently selected from C and N; provided that when U is N, R 2 is absent; when V is N, R 3 is absent; and when W is N, R 4 is absent;
• R 2 and R 3 are each independently selected from -H, -halo, -CN, C 1.4 alkyl substituted with 0-3 substituents selected from -F and -OMe, C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe, C 3-4 cycloalkyl substituted with 0-3 substituents selected from -F and -OMe, and C 3-4 cycloalkoxy substituted with 0-3 substituents selected from -F and -Me; and R 4 is selected from -F and C 1-4 alkoxy substituted with 0-3 substituents selected from -F and -OMe; optionally R 4 is C 1.4 alkoxy substituted with 0-3 substituents selected from -F and - OMe; optionally R 4 is -OMe.
• Ring B is a 5- to 8-membered cycloalkyl, or a 5- to 8-membered cycloalkenyl
• R 7 is selected from -H and -F; each R 8 is independently selected from C 1.2 alkyl substituted with 0-3 -F substituents; and
• p is 0 or 1; optionally p is 0;
• R 1 is selected from - X is -O-; r is 1 or 2;
• R 5 is -H
• R 6 is -(CR 10 R u )nR 12 ; n is 0 or 1; optionally n is 1;
• R 10 and R 11 are each independently selected from -H, -Me and -F, or R 10 and R 11 together with the carbon to which they are attached form cyclopropyl;
• R 12 is selected from C 4-6 alkyl substituted with 0-3 substituents selected from -F, -CN, and C 1-2 alkoxy;
• each R 13 is independently selected from -F; -CN; C 1.2 alkoxy substituted with 0-1 substituents selected from -F, -OMe and -OEt; and C 1.2 alkyl substituted with 0-1 substituents selected from -F, -OMe and -OEt;
• R 2 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and cyclopropyl; optionally R 2 is -F or -CN;
• R 3 is selected from -H, -halo, -CN, C 1.2 alkyl substituted with 0-3 -F substituents, C 1.2 alkyl substituted with 0-1 -OMe substituents, and cyclopropyl; optionally R 3 is -H;
• R 4 is selected from -F and C 1.4 alkoxy substituted with 0-3 substituents selected from -F and -OMe; optionally R 4 is C 1.4 alkoxy substituted with 0-3 substituents selected from -F and - OMe; optionally R 4 is -OMe.
• a compound of Formula (Ila) or Formula (lib), or a pharmaceutically acceptable salt thereof wherein
• Formula (I) there is provided a compound of Formula (IVa) or Formula (IVb), or a pharmaceutically acceptable salt thereof, wherein R 2 is -F or -CN; and R 6 is selected from
• the compound of Formula (I) is pharmaceutically acceptable salt thereof.
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of Formula (I) is pharmaceutically acceptable salt thereof.
• the compound of Formula (I) is pharmaceutically acceptable salt thereof. In an embodiment, the compound of Formula (I) is pharmaceutically acceptable salt thereof. In an embodiment, the compound of Formula (I) is pharmaceutically acceptable salt thereof.
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of Formula (I) is pharmaceutically acceptable salt thereof.
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• the compound of Formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• a compound is provided that is any one of the compounds from COMPOUND LIST A, or a pharmaceutically acceptable salt thereof. In an embodiment, a compound is provided that is any one of the compounds from COMPOUND LIST A.
• the compound of Formula (I) is selected from the compounds of COMPOUND LIST A, or pharmaceutically acceptable salts thereof. In an embodiment, the compound of Formula (I) is selected from the compounds of

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Cardiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Hospice & Palliative Care (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=78916968

Family Applications (1)

Country Status (19)

Cited By (10)

Families Citing this family (1)

Citations (1)

Family Cites Families (2)

• 2021
  • 2021-12-07 EP EP21824574.4A patent/EP4259605A1/en active Pending
  • 2021-12-07 CN CN202180075461.3A patent/CN116547270A/zh active Pending
  • 2021-12-07 CR CR20230296A patent/CR20230296A/es unknown
  • 2021-12-07 JP JP2023534685A patent/JP2023552793A/ja active Pending
  • 2021-12-07 WO PCT/EP2021/084673 patent/WO2022122773A1/en not_active Ceased
  • 2021-12-07 IL IL303220A patent/IL303220A/en unknown
  • 2021-12-07 TW TW110145574A patent/TW202237559A/zh unknown
  • 2021-12-07 CA CA3203024A patent/CA3203024A1/en active Pending
  • 2021-12-07 KR KR1020237022785A patent/KR20230118142A/ko active Pending
  • 2021-12-07 US US17/457,953 patent/US11667602B2/en active Active
  • 2021-12-07 AU AU2021395353A patent/AU2021395353B2/en active Active
  • 2021-12-07 AR ARP210103397A patent/AR124193A1/es unknown
  • 2021-12-07 PE PE2023001826A patent/PE20240655A1/es unknown
  • 2021-12-07 MX MX2023006178A patent/MX2023006178A/es unknown
  • 2021-12-08 UY UY0001039559A patent/UY39559A/es unknown
• 2023
  • 2023-02-22 US US18/172,449 patent/US20230348363A1/en active Pending
  • 2023-06-01 CL CL2023001572A patent/CL2023001572A1/es unknown
  • 2023-06-05 DO DO2023000111A patent/DOP2023000111A/es unknown
  • 2023-06-26 CO CONC2023/0008303A patent/CO2023008303A2/es unknown
  • 2023-07-04 EC ECSENADI202350133A patent/ECSP23050133A/es unknown

Patent Citations (1)

Non-Patent Citations (27)

Also Published As

Similar Documents

Legal Events